Work Here?
Overview
Rotech Healthcare provides non-invasive daytime therapy for people with mild obstructive sleep apnea (OSA) and snoring using its eXciteOSA device. The device uses intraoral electrical muscle stimulation and is worn during the day to train the muscles that support breathing, with clinical data showing improvements in nighttime sleep and reduced snoring. It differentiates itself by offering a daytime, easy-to-use solution that targets mild OSA and chronic snoring, backed by FDA authorization and direct sales through its website and authorized distributors. The goal is to improve sleep quality and overall well-being by reducing OSA symptoms and snoring.
About Rotech Healthcare
Industries
Healthcare
Consumer Goods
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
$6.5M
Headquarters
Orlando, Florida
Founded
1981
Get referred to Rotech Healthcare
See people who can refer or advise you
Simplify's Take
What believers are saying
- Rotech launched eXciteOSA distribution with Signifier on February 5, 2026.
- CQRC's 2026 SOAR Act push favors home respiratory reimbursement and Rotech's core business.
- Rotech still operates 325 locations, preserving national patient access and cross-sell opportunities.
What critics are saying
- Three sealed FCA cases in S.D.N.Y. target Rotech billing, AKS, and retaliation practices.
- Rotech resolved a 2018 Medicare billing case; repeat billing scrutiny damages payer trust.
- Owens & Minor terminated the 2024 acquisition in June 2025, signaling valuation and diligence stress.
What makes Rotech Healthcare unique
- Rotech's 2024 Signifier partnership adds FDA-approved eXciteOSA distribution across home-care channels.
- Rotech's 325-location network and 46-state footprint create difficult-to-replicate respiratory delivery reach.
- Robin Menchen chairs CQRC in 2026, giving Rotech regulatory influence on oxygen reform.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$6.5M
Above
Industry Average
Funded Over
2 Rounds
Growth & Insights and Company News
6 month growth
↑ 13%1 year growth
↑ 13%2 year growth
↑ 13%Owens & Minor (OMI) reported a Q4 2024 net loss of $(311)-(288) million due to a $310 million non-cash goodwill impairment in its Apria division. Q4 revenue is expected to be $2.67-$2.70 billion, with full-year revenue at $10.67-$10.70 billion. The company reduced total debt by over $240 million in 2024. Adjusted EBITDA for Q4 is projected at $135-$140 million, and $520-$525 million for the full year. Full financial results will be released on February 28, 2025.
Owens & Minor (NYSE: OMI) has signed a definitive agreement to acquire Rotech Healthcare Holdings for $1.36 billion in cash, with a net purchase price of approximately $1.32 billion after tax benefits. Rotech generated about $750 million in revenue with an EBITDA margin of nearly 30% in 2023. The acquisition aligns with Owens & Minor's strategy to expand in home-based care. The deal is expected to close by the end of 2024 and achieve $50 million in synergies by year three.
Under the terms of the agreement, which was unanimously approved by the Board of Directors of each company, Owens & Minor will acquire Rotech for $1.36 billion in an all-cash transaction.
Home respiratory care provider Rotech Healthcare has appointed Barry Stewart as CFO, effective immediately.
There are no jobs for Rotech Healthcare right now.
Find jobs on Simplify and start your career today
About Rotech Healthcare
Industries
Healthcare
Consumer Goods
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
$6.5M
Headquarters
Orlando, Florida
Founded
1981
There are no jobs for Rotech Healthcare right now.
Find jobs on Simplify and start your career today